CASE STUDY
PRESENTATION
Presented By:
Niro, Ronz Frech T. Laoat, Roshele D.
Biton, Eiya Krestel I. Gabor, Kathreena R.
Eliarda, Gwynette Stephanie C. Preposi, Christine Joyce A.
Mosuela, Jea Marie C.
Michael Angelo B. Salgado, RMT
Adviser
Pseudomonas aeruginosa
Infection in a Leukemia Patient:
A Case Study of Sepsis in an
Immunocompromised Host
Introduction
The case study examines some of the very complicated diagnostic and
therapeutic challenges brought up by a chemotherapy-treated leukemia
patient who became sepsis-prone because of highly drug-resistant
Pseudomonas aeruginosa.
The purpose of this case is to clarify the difficulties in identifying and treating
P. aeruginosa infections in leukemia patients, especially those receiving
chemotherapy.
This case highlights the vital significance of early detection, precise diagnosis,
and customized treatment approaches in enhancing patient outcomes by
analyzing the interaction of immunosuppression, pathogen virulence, and
antibiotic resistance.
II. CASE PRESENTATION
Age/Sex/History : 44-year-old female , undergoing
chemotherapy for leukemia.
Chief Complaint: fever, dyspnea, and hypotension starting
suddenly
Clinical Course: 24 hours the patient experienced mucositis,
fever, dyspnea, and hypotension.
Microbiological Findings: Blood cultures, Gram Negative rods,
non-fermenting, grows at 42 °C
Diagnosis: Sepsis brought on in a neutropenic host by
Pseudomonas aeruginosa.
Laboratory Findings
Test Result
Blood Culture (Gram-Stain) Gram-negative rods
Blood Culture (Organism Identified) Pseudomonas aeruginosa
Growth at 42°C (+)
Oxidase Test (+)
Urease Test (-)
Lactose Fermentation (MacConkey Agar) (-)
Resistant to Piperacillin, tazobactam, Meropenem,
Antimicrobial Susceptibility Testing Ciprofloxacin
Sensitive to Colistin, Amikacin
III. ANALYSIS OF DATA
Diagnostic Flowchart
IV. DISCUSSION
HISTORY, ETIOLOGY AND EPIDEMIOLOGY
PATHOPHYSIOLOGY
ANTIMICROBIAL THERAPHY
Group of Antibiotics Old New
Ceftazidime
Ceftolozane/tazobactam
Cefepime
Ceftazidime/avibactam
Piperacillin/tazobactam
β-lactams Meropenem/vaborbactam
Imipenem
Imipenem/relebactam
Meropenem
Cefiderocol
Aztreonam
Ciprofloxacin
Fluoroquinolones
Levofloxacin
Amikacin
Aminoglycosides Plazomycin
Tobramycin
Polymyxins Colistin
Phosphonates Fosfomycin
V. CONCLUSION
The case of a 44-year-old leukemia patient and the major difficulty that is
created by Pseudomonas aeruginosa in an immunocompromised host were
described. This sudden severe symptoms are associated with strains of these
agents that are multidrug resistant highlighting the need for early diagnosis
and reactors of suitable effectiveness.
Improving infection control, developing new antibiotics, and strengthening
antimicrobial stewardship to manage Pseudomonas aeruginosa infections in
high risk patients like those with leukemia.
REFERENCES:
Andremont, A., Marang, B., Tancrède, C., Baume, D., & Hill, C. (1989). Antibiotic treatment and intestinal colonization by Pseudomonas
aeruginosa in cancer patients. Antimicrobial Agents and Chemotherapy, 33(8), 1400–1402. https://doi.org/10.1128/aac.33.8.1400
Barragán, E. P., Pérez, J. S., Corbella, L., Orellana, M. Á., & Fernández-Ruiz, M. (2018, July 12). Achromobacter xylosoxidans bacteremia: clinical
and microbiological features in a 10-year case series. https://pmc.ncbi.nlm.nih.gov/articles/PMC6166261/
Bodey, G. P., Bolivar, R., Fainstein, V., & Jadeja, L. (1983). Infections caused by Pseudomonas aeruginosa. Reviews of Infectious Diseases, 5(2), 279–
313. https://doi.org/10.1093/clinids/5.2.279
Brown, M. R. W. (1975). Resistance of pseudomonas aeruginosa. John Wiley & SonsChennamadhavuni, A., Lyengar, V., Mukkamalla, S. K. R., &
Shimanovsky, A. (2023b, January 17). Leukemia. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK560490/
Ciofu, O., & Tolker-Nielsen, T. (2019). Tolerance and Resistance of Pseudomonas aeruginosa Biofilms to Antimicrobial Agents—How P.
aeruginosa Can Escape Antibiotics. Frontiers in Microbiology, 10. https://doi.org/10.3389/fmicb.2019.00913
Clinical and Laboratory Standards Institute (CLSI). (2021). Performance standards for antimicrobial susceptibility testing(31st ed.). CLSI
document M100. Clinical and Laboratory Standards Institute.
Crone, S., Vives‐Flórez, M., Kvich, L., Saunders, A. M., Malone, M., Nicolaisen, M. H., ... & Bjarnsholt, T. (2020). The environmental occurrence of
Pseudomonas aeruginosa. Apmis, 128(3), 220-231.
De Sousa, T., Hébraud, M., Dapkevicius, M. L. E., Maltez, L., Pereira, J. E., Capita, R., ... & Poeta, P. (2021). Genomic and Metabolic Characteristics
of the Pathogenicity in Pseudomonas aeruginosa. International journal of molecular sciences, 22(23), 12892.
Garnacho-Montero, J., Garcia-Garmendia, J. L., Barrero-Almodovar, A., Jimenez-Jimenez, F. J., Perez-Paredes, C., & Ortiz-Leyba, C. (2003).
Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis*. Critical Care
Medicine, 31(12), 2742–2751. https://doi.org/10.1097/01.ccm.0000098031.24329.10
Gudiol, C., Durà-Miralles, X., Aguilar-Company, J., Hernández-Jiménez, P., Martínez-Cutillas, M., Fernandez-Avilés, F., Machado, M., Vázquez, L.,
Martín-Dávila, P., De Castro, N., Abdala, E., Sorli, L., Andermann, T., Márquez-Gómez, I., Morales, H., Gabilán, F., Ayaz, C., Kayaaslan, B., Aguilar-
Guisado, M., . . . Carratalà, J. (2021). Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international
study. Journal of Infection, 83(3), 306–313. https://doi.org/10.1016/j.jinf.2021.07.014
Horcajada, J. P., Montero, M., Oliver, A., Sorlí, L., Luque, S., Gómez-Zorrilla, S., Benito, N., & Grau, S. (2019). Epidemiology and Treatment of
Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clinical Microbiology Reviews, 32(4).
https://doi.org/10.1128/cmr.00031-19
THANK YOU
